Abstract | BACKGROUND: METHODS: RESULTS:
Folic acid treatment lowered plasma homocysteine significantly by 39% (95% CI 5 to 73) in the ESRD group, but plasma homocysteine remained higher than baseline values in the control group. In ESRD patients, homocysteine remethylation and methionine transmethylation rate increased by 34% (95% CI 5 to 62) and 22% (95% CI 5 to 39), respectively (i.e., levels that were similar to the baseline values of the control group). Transsulfuration rate and metabolic homocysteine clearance were not significantly altered by folic acid treatment in both the ESRD and the control group. CONCLUSION:
|
Authors | Frank Stam, Coen van Guldener, Piet M Ter Wee, Cornelis Jakobs, Kees de Meer, Coen D A Stehouwer |
Journal | Kidney international
(Kidney Int)
Vol. 67
Issue 1
Pg. 259-64
(Jan 2005)
ISSN: 0085-2538 [Print] United States |
PMID | 15610249
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Homocysteine
- Folic Acid
- Methionine
|
Topics |
- Administration, Oral
- Adult
- Aged
- Case-Control Studies
- Female
- Folic Acid
(administration & dosage, therapeutic use)
- Homocysteine
(blood, metabolism)
- Humans
- Hyperhomocysteinemia
(blood, drug therapy, etiology)
- Kidney Failure, Chronic
(complications, drug therapy, metabolism, therapy)
- Kinetics
- Male
- Methionine
(metabolism)
- Methylation
- Middle Aged
- Renal Dialysis
|